Loading patent…
AssigneeInstituto Bioclon, S.A. de C.V.
InventorsJuan Lopez de Silanes, Rita G. Mancilla-Nava, Jorge F. Paniagua-Solis
Estimating the term…
The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab′)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab′)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.
A method for the preparation of F(ab′)2 antibody fragments comprising the following steps:
A pharmaceutical composition comprising polyclonal F(ab′)2 antibody fragments free from albumin and whole antibodies and substantially free of pyrogens, wherein the F(ab′)2 binds to a purified molecule.
A pharmaceutical composition comprising polyclonal anti-TNF-α F(ab′)2 antibody fragments free from albumin and whole antibodies and substantially free of pyrogens.
A pharmaceutical composition comprising polyclonal F(ab′)2 antibody fragments free from albumin and whole antibodies and substantially free of pyrogens, wherein the F(ab′)2 antibody fragments are obtained by the method which comprises:
Dependencies are inferred from the claim text.